Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Marshall Financial Group LLC

Marshall Financial Group LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 8.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,437 shares of the biopharmaceutical company’s stock after purchasing an additional 2,124 shares during the quarter. Marshall Financial Group LLC’s holdings in Bristol-Myers Squibb were worth $1,542,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $34,000. VisionPoint Advisory Group LLC grew its holdings in shares of Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 553 shares during the period. Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 1.0 %

Shares of NYSE BMY traded down $0.39 during mid-day trading on Thursday, hitting $40.06. The company had a trading volume of 9,131,450 shares, compared to its average volume of 16,023,750. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38. The company has a market capitalization of $81.21 billion, a PE ratio of -12.92, a price-to-earnings-growth ratio of 13.84 and a beta of 0.44. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The business’s 50-day simple moving average is $42.46 and its 200 day simple moving average is $47.91.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.99%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Analyst Ratings Changes

Several analysts have recently weighed in on BMY shares. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays decreased their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.